Replimune Announces Sander Slootweg will Depart from its Board of Directors
20 Julho 2023 - 9:00AM
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage
biotechnology company pioneering the development of a novel class
of tumor-directed oncolytic immunotherapies, today announced Sander
Slootweg, founder and managing partner at Forbion, will not seek to
be reappointed as a non-executive director at the end of his
current term at the company’s upcoming annual general meeting.
“It has been a pleasure working with Sander since the inception
of Replimune several years ago,” said Philip Astley-Sparke, CEO of
Replimune. “We are grateful for Sander’s sage advice, expertise and
Forbion’s support of Replimune, and the other directors and members
of our executive team join me in wishing Sander continued
success.”
“I am incredibly proud of being part of the board, and
especially in what Replimune has accomplished since the company’s
founding,” said Sander Slootweg, founder and managing partner at
Forbion. “It was our belief from the start that tumor-directed
oncolytic immunotherapy had immense potential to benefit patients
in a variety of cancers, and I believe the company is well
positioned to fulfill its promise.”
About Replimune Replimune Group, Inc.,
headquartered in Woburn, MA, was founded in 2015 with the mission
to transform cancer treatment by pioneering the development of
novel tumor-directed oncolytic immunotherapies. Replimune’s
proprietary RPx platform is based on a potent HSV-1 backbone with
payloads added to maximize immunogenic cell death and the induction
of a systemic anti-tumor immune response. The RPx platform has a
unique dual local and systemic mechanism of action consisting of
direct selective virus-mediated killing of the tumor resulting in
the release of tumor derived antigens and altering of the tumor
microenvironment to ignite a strong and durable systemic response.
This MOA is expected to be synergistic with most established and
experimental cancer treatment modalities, and, with an attractive
safety profile the RPx platform has the versatility to be developed
alone or combined with a variety of other treatment options. For
more information, please visit www.replimune.com.
Forward Looking Statements This press release
contains forward looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, including
statements regarding the design and advancement of our clinical
trials, the timing and sufficiency of our clinical trial outcomes
to support potential approval of any of our product candidates, our
goals to develop and commercialize our product candidates, patient
enrollments in our existing and planned clinical trials and the
timing thereof, and other statements identified by words such as
“could,” “expects,” “intends,” “may,” “plans,” “potential,”
“should,” “will,” “would,” or similar expressions and the negatives
of those terms. Forward-looking statements are not promises or
guarantees of future performance, and are subject to a variety of
risks and uncertainties, many of which are beyond our control, and
which could cause actual results to differ materially from those
contemplated in such forward-looking statements. These factors
include risks related to our limited operating history, our ability
to generate positive clinical trial results for our product
candidates, the costs and timing of operating our in-house
manufacturing facility, the timing and scope of regulatory
approvals, changes in laws and regulations to which we are subject,
competitive pressures, our ability to identify additional product
candidates, political and global macro factors including the impact
of the coronavirus as a global pandemic and related public health
issues, and other risks as may be detailed from time to time in our
Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and
other reports we file with the Securities and Exchange Commission.
Our actual results could differ materially from the results
described in or implied by such forward-looking statements.
Forward-looking statements speak only as of the date hereof, and,
except as required by law, we undertake no obligation to update or
revise these forward-looking statements.
Investor Inquiries Chris BrinzeyWestwicke, an
ICR Company339.970.2843chris.brinzey@westwicke.com
Media InquiriesArleen
GoldenbergReplimune917.548.1582media@replimune.com
Replimune (NASDAQ:REPL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Replimune (NASDAQ:REPL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024